A Complex Intervention for Chronically Fatigued Lymphoma Survivors
NCT05130099 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2024-04-08
Summary
The present study is a randomized controlled trial (RCT) with an overall objective to examine the effect of an interdisciplinary complex intervention on the level of fatigue in lymphoma survivors with chronic fatigue. Secondary aims are to examine the effects of the intervention on daily functioning, work status/ability, physical fitness and QoL among the survivors, on QoL of their relatives and on the societal costs.The intervention will last for 12+12 weeks and include four components; patient education, supervised physical exercise, cognitive behavioral program and nutritional counselling. Outcomes will be assessed at baseline,post-intervention (12 weeks after baseline) and at 3-month, 6-month, 12-month and 24-month follow-up after completed intervention.
Conditions
- Chronic Fatigue Syndrome
Interventions
- OTHER
-
Interdisciplinary complex intervention
The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components; Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF). Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks. Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes. Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes.
Sponsors & Collaborators
-
University of Oslo
collaborator OTHER -
Norwegian School of Sport Sciences
collaborator OTHER -
UiT The Arctic University of Norway
collaborator OTHER -
Norwegian University of Science and Technology
collaborator OTHER -
Diakonhjemmet Hospital
collaborator OTHER -
University of Alberta
collaborator OTHER -
St. Olavs Hospital
collaborator OTHER -
Oslo University Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-20
- Primary Completion
- 2023-06-30
- Completion
- 2025-06-30
Countries
- Norway
Study Locations
More Related Trials
-
Diet, Physical Activity and Body Composition Changes During R-CHOP
NCT04293900 ·Status: WITHDRAWN
-
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
NCT02896829 ·Status: COMPLETED
-
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
NCT04982471 ·Status: TERMINATED
-
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
NCT00691652 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
NCT05934084 ·Status: RECRUITING ·Phase: NA
-
Navigating the Clinical Research Process for Lymphoma
NCT06070246 ·Status: NOT_YET_RECRUITING
-
Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma
NCT00903890 ·Status: COMPLETED
-
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
NCT00052923 ·Status: COMPLETED ·Phase: PHASE3
-
Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant
NCT02109809 ·Status: TERMINATED ·Phase: NA
-
Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
NCT06890091 ·Status: NOT_YET_RECRUITING
-
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
NCT05237245 ·Status: ACTIVE_NOT_RECRUITING
-
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT01419795 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
NCT00064116 ·Status: COMPLETED ·Phase: PHASE3
-
Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
NCT05524298 ·Status: RECRUITING
-
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
NCT00022971 ·Status: TERMINATED ·Phase: PHASE1
-
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
NCT00071396 ·Status: COMPLETED ·Phase: PHASE2
-
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
NCT06923397 ·Status: RECRUITING ·Phase: NA
-
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma
NCT06161896 ·Status: RECRUITING
-
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
NCT01359592 ·Status: COMPLETED ·Phase: PHASE2
-
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521 ·Status: RECRUITING ·Phase: NA
-
A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).
NCT00301314 ·Status: COMPLETED
-
IMPACT Non Hodgkins Lymphoma (NHL) Study
NCT00903812 ·Status: COMPLETED
-
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089 ·Status: COMPLETED ·Phase: PHASE2
-
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00521261 ·Status: WITHDRAWN ·Phase: PHASE1
-
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
NCT00209209 ·Status: UNKNOWN ·Phase: PHASE3